Sobi's PhIII gout win sets up a potential rivalry with future Amgen asset
Almost three years after Swedish Orphan Biovitrum — perhaps better known as Sobi — shelled out $100 million in cash to license Selecta’s experimental drug for chronic refractory gout, the partners have clinched the Phase III data they were striving for.
The drug, SEL-212, met the primary endpoint across two trials in a Phase III program, the companies reported, measured by the percentage of patients achieving a response. They added that there was no difference in gout flares between the treatment and placebo arms at the six-month time point, a secondary endpoint, suggesting the drug was able to suppress gout flares.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters